Apremilast in the Treatment of Uveitis
NCT00889421 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3
Last updated 2014-07-08
Summary
The purpose of this study is to assess the safety and efficacy of Apremilast in the treatment of uveitis.
Conditions
- Uveitis
Interventions
- DRUG
-
Apremilast
oral dose of 30 mg BID for 6 months
Sponsors & Collaborators
-
Oregon Health and Science University
lead OTHER -
Celgene Corporation
collaborator INDUSTRY
Principal Investigators
-
Eric B Suhler, MD, MPH · Oregon Health and Science University
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-11-30
- Primary Completion
- 2011-06-30
- Completion
- 2011-06-30
Countries
- United States
Study Locations
More Related Trials
-
Study of Risk Factors for Therapeutic Failure in Chronic Non-Infectious Uveitis After First-Line Immunosuppressive Therapy
NCT06821971 ·Status: ACTIVE_NOT_RECRUITING
-
Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis
NCT03207815 ·Status: TERMINATED ·Phase: PHASE2
-
Methotrexate and Mycophenolate Mofetil for UVEITIS
NCT01829295 ·Status: COMPLETED ·Phase: PHASE3
-
Intravitreal Sirolimus as Therapeutic Approach to Uveitis
NCT01280669 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
NCT01032915 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis
NCT04798755 ·Status: UNKNOWN ·Phase: PHASE3
-
Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients
NCT02252328 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis
NCT03066869 ·Status: UNKNOWN ·Phase: PHASE4
-
Leflunomide to Treat Uveitis
NCT00001863 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of MM-093 to Treat Patients With Uveitis
NCT00444743 ·Status: COMPLETED ·Phase: PHASE2
-
ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)
NCT02931175 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis
NCT01327664 ·Status: WITHDRAWN ·Phase: PHASE3
-
Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
NCT00615693 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
NCT01095250 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis
NCT05105347 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
NCT00404885 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment FOr Corticosteroid Dependent UveitiS
NCT06258915 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
NCT00415506 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of AIN457 in Noninfectious Uveitis
NCT00685399 ·Status: COMPLETED ·Phase: PHASE2
-
Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients
NCT05155592 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
NCT01090310 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluation and Treatment of Patients With Inflammatory Eye Diseases
NCT00006188 ·Status: COMPLETED
-
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
NCT01103024 ·Status: WITHDRAWN ·Phase: PHASE3
-
Microbiome as a ThErapeutic Response Biomarker
NCT04721743 ·Status: WITHDRAWN
-
Use of Thalidomide in Chronic Uveitis
NCT00314665 ·Status: TERMINATED ·Phase: PHASE4